Hcmed Innovations Co

Hcmed Innovations Co Diluted EPS

The Diluted Earnings per Share of Hcmed Innovations Co (6934.TWO) as of Nov 5, 2026 is -3.84 TWD. In the previous year, Diluted Earnings per Share was -2.59 TWD — a change of 48.28% (lower).

Diluted EPS

-3.84TWD

YoY

48.28%

Last updated:

Diluted Earnings per Share of Hcmed Innovations Co is 2025 -3.84 TWD. Diluted Earnings per Share of Hcmed Innovations Co was 2024 -2.59 TWD. It decreases by 48.28% lower compared to the previous year.

The Hcmed Innovations Co Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2020
-2.51 TWD
Jan 1, 2021
-2.29 TWD
Jan 1, 2022
-6.66 TWD
Jan 1, 2023
-6.76 TWD
Jan 1, 2024
-2.59 TWD
Jan 1, 2025
-3.84 TWD
The Hcmed Innovations Co Diluted EPS history
YEARDiluted EPSYoY
-3.84TWD+48.28%
-2.59TWD-61.69%
-6.76TWD+1.49%
-6.66TWD+190.80%
-2.29TWD-8.68%
-2.51TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hcmed Innovations Co Stock analysis

What does Hcmed Innovations Co do? Hcmed Innovations Co Ltd generates revenue through the design, development, production, and sales of handheld medical nebulizers tailored to pharmaceutical companies' requirements. The company offers vibrating mesh nebulizers that adjust oscillation frequency for effective drug delivery to the lower respiratory tract without specialized breathing techniques, targeting conditions like chronic obstructive pulmonary disease, asthma, cystic fibrosis, and respiratory infections. Additionally, Hcmed provides contract development and manufacturing organization (CDMO) services for drug-specific nebulizers, focusing on inhalation dosage form design and development. Key markets include the United States, Taiwan, Switzerland, Israel, and the United Kingdom, where pharmaceutical companies purchase these specialized medical devices and services. The company's primary products are vibrating mesh nebulizers and CDMO services for pharmaceutical clients. Vibrating mesh nebulizers are designed to deliver medications efficiently to the respiratory system, while CDMO services support the creation of nebulizers optimized for specific drugs. These offerings are sold to pharmaceutical companies seeking to enhance their inhalation therapy solutions. The United States, Taiwan, Switzerland, Israel, and the United Kingdom represent the main geographic segments driving sales, with pharmaceutical firms as the core customer base. Hcmed Innovations Co Ltd monetizes its expertise in medical device development by supplying both hardware and specialized manufacturing services. The vibrating mesh nebulizer technology enables precise drug delivery, addressing high-demand respiratory conditions. CDMO services further capitalize on the growing need for customized inhalation therapies, with pharmaceutical companies as the primary buyers. Sales are concentrated in the United States, Taiwan, Switzerland, Israel, and the United Kingdom, reflecting the global reach of its target market. Hcmed Innovations Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hcmed Innovations Co stock

Diluted Earnings per Share of Hcmed Innovations Co is -3.84 TWD in 2025.

Diluted Earnings per Share of Hcmed Innovations Co changed from -2.59 TWD to -3.84 TWD, representing a 48.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Hcmed Innovations Co since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Hcmed Innovations Co

All Key Metrics — Hcmed Innovations Co